07:00 , Apr 14, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Nuclear factor of activated T cells cytoplasmic calcineurin-dependent 3 (NFATc3; NFAT4); protein phosphatase 3 regulatory subunit B α (PPP3R1)

Cancer INDICATION: Colorectal cancer Patient sample and mouse studies suggest inhibiting NFATc3 or PPP3R1 could help treat colorectal cancer (CRC). In CRC patients, NFATc3 nuclear activity in tumor cells correlated with poor survival and NFATc3...
08:00 , Feb 18, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Nuclear factor of activated T cells cytoplasmic calcineurin-dependent 3 (NFATc3; NFAT4)

Inflammation INDICATION: Shock / trauma Rat studies suggest inhibiting NFATc3 could help treat traumatic brain injury (TBI). In a rat model of TBI, NFATc3 and astrocytes co-localized in the hippocampus seven days post-injury. In hippocampal...
07:00 , Jun 17, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology; nerve damage Glycogen dependent kinase 3 (GSK3); nuclear factor of activated T cells cytoplasmic calcineurin-dependent 3 (NFATC3; NFAT4); NFATC4 (NFAT3) A study in mice...